Evidence map›Paper›PMID 7705840›Full record

ArticleHuman genetics1995

New polymorphisms and markers in the HLA class I region: relevance to hereditary hemochromatosis (HFE).

A Totaro, A Grifa, A Roetto, C Lunardi, L D'Agruma, L Sbaiz, L Zelante, G De Sandre, C Camaschella, P Gasparini

Abstract read
PubMed Publisher
In one paragraph

Article in Human genetics, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

A TotaroServizio di Genetica Medica, IRCCS-Ospedale CSS, San Giovanni Rotondo (FG), Italy.
A Grifa
A Roetto
C Lunardi
L D'Agruma
L Sbaiz
L Zelante
G De Sandre
C Camaschella
P Gasparini
Istituti di Ricovero e Cura a Carattere Scientifico · ITNuovo Ospedale San Giovanni di Dio · ITUniversity of Verona · ITTorino e-district · IT

Funding

Telethon E.0032
6 · The paper itself

Abstract

Hereditary hemochromatosis (HFE) is an inherited disorder whose gene lies in the proximity of the histocompatibility antigen (HLA) class I region, on 6p21.3. Despite efforts in refining the HFE region, a number of informative DNA markers, linked to the disease locus and amenable to use in an assay based on the polymerase chain reaction (PCR) is available. The gene content of this region is high, and the HFE gene has not so far been identified. We have used a strategy based on PCR protocols potentially able to detect both polymorphisms and expressed sequences. This approach has been applied to a 700-kb stretch (approximately) of DNA corresponding to the insert of a Centre d'Etude du Polymorphisme Humain yeast artificial chromosome (225 B1) of the possible candidate region. Five new polymorphisms have been detected among 20 specific fragments isolated. Four of them are tightly linked to the HFE locus. Because of the strong linkage disequilibrium with the disease demonstrated by these markers, they could represent starting points for the identification and characterization of the HFE gene. The remaining non-polymorphic fragments, being amplifiable and in most cases linked to NotI sites, may be useful starting points for the generation of a genomic contig of band 6p21.3 and for gene identification.

Indexed as

Genetic MarkersPolymorphism, GeneticBase SequenceBlotting, NorthernDNADNA PrimersGenetic LinkageHemochromatosisHistocompatibility Antigens Class IHumansMolecular Sequence DataPolymerase Chain ReactionDNADNA PrimersGenetic MarkersHistocompatibility Antigens Class I

Identifiers

PMID7705840
OpenAlexW1977712298

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.